These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 25960634)

  • 1. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
    Nguyen TT; Guymer R
    Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
    Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
    Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
    [No Abstract]   [Full Text] [Related]  

  • 4. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
    Liu K; Song Y; Xu G; Ye J; Wu Z; Liu X; Dong X; Zhang M; Xing Y; Zhu S; Chen X; Shen Y; Huang H; Yu L; Ke Z; Rosenfeld PJ; Kaiser PK; Ying G; Sun X; Xu X;
    Am J Ophthalmol; 2019 Jan; 197():156-167. PubMed ID: 30148987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
    Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
    Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation.
    Zhang X; Zhuang X; Dong J; Fu B; Zhang G; Xu L
    Adv Clin Exp Med; 2024 Apr; 33(4):335-342. PubMed ID: 37747440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aflibercept for the treatment of neovascular age-related macular degeneration.
    Verner-Cole EA; Davis SJ; Lauer AK
    Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
    Dixon JA; Oliver SC; Olson JL; Mandava N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
    Yang S; Zhao J; Sun X
    Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
    Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
    Budzinskaya MV; Plyukhova AA; Sorokin PA
    Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on conbercept to treat wet age-related macular degeneration.
    Ferro Desideri L; Traverso CE; Nicolò M
    Drugs Today (Barc); 2020 May; 56(5):311-320. PubMed ID: 32406878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration.
    Falavarjani KG; Sadda SR
    Curr Pharm Des; 2017; 23(4):535-541. PubMed ID: 27981904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
    Cui C; Lu H
    Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
    Teo KYC; Gillies M; Fraser-Bell S
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
    Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
    Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.
    Jing J; Yinchen S; Xia C; Jing W; Chong C; Xun X; Hengye H; Kun L
    BMC Ophthalmol; 2018 Jul; 18(1):181. PubMed ID: 30041608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.